--- canonical_name: sh-Oligopeptide-4 alternate_names: Thymosin Beta-4, Thymosin β4, Tβ4, rhTβ4, CG-Thymosin β4, Timbetasin, Human Oligopeptide-16 canonical_topic: sh-Oligopeptide-4 for Hair Regrowth short_topic_lc: sh_oligopeptide_4_hair creation_date: 2026-0825-1456 creator_ai_fullname: Grok 4.5 --- # sh-Oligopeptide-4 for Hair Regrowth
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Grok 4.5 **Also known as:** Thymosin Beta-4, Thymosin β4, Tβ4, rhTβ4, CG-Thymosin β4, Timbetasin, Human Oligopeptide-16 ## Motivation sh-Oligopeptide-4 is a laboratory-made copy of thymosin beta-4, a small protein already present in almost every human cell. Hair serums list it as a follicle-stimulating cosmetic ingredient, and some clinics place related peptide blends into the scalp. Interest comes from animal work showing faster hair growth and from the protein's role in moving cells and growing tiny blood vessels around injured tissue. Hair interest began when researchers treating rodent skin wounds noticed denser hair at the wound edge. Cosmetic manufacturers later formulated a laboratory-made version. Drug developers separately tested the same protein for eye and heart repair. Human trials that isolate this peptide and count scalp hairs have not been published. One study of living human follicles grown outside the body found slightly less hair-shaft growth. This review examines whether the cosmetic peptide, used for hair regrowth, has human outcome evidence, how it is thought to act, what follows from its vessel-growing and cell-moving actions, and how marketed products relate to the molecule studied in laboratories. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading High-level sources that frame sh-Oligopeptide-4 as a lab-made copy of thymosin beta-4 and its proposed action on hair-follicle stem cells. - [Multiple potential roles of thymosin β4 in the growth and development of hair follicles](https://pubmed.ncbi.nlm.nih.gov/33393222/) - Dai et al., 2021 Maps endogenous and applied thymosin beta-4 onto follicle cycling, stem-cell migration, and the rodent plus cashmere-goat data that cosmetic hair claims rest on. - [Thymosin beta4 increases hair growth by activation of hair follicle stem cells](https://pubmed.ncbi.nlm.nih.gov/14657002/) - Philp et al., 2004 Original National Institutes of Health report that topical thymosin beta-4 recruited bulge keratinocytes, raised protease activity, and sped hair growth in rats and mice. - [Benefits & Risks of Peptide Therapeutics for Physical & Mental Health](https://www.hubermanlab.com/episode/benefits-risks-of-peptide-therapeutics-for-physical-mental-health) - Andrew Huberman Solo episode with chapters on thymosin beta-4 and TB-500 for tissue repair and longevity, naming the parent peptide and the fragment gray-market vials often substitute. - [Thymosin beta 4 and Skin Repair](https://www.lifeextension.com/magazine/2002/2/report_tb4) - Carmia Borek Life Extension Magazine overview of thymosin beta-4 as a wound-healing, actin-linked skin-repair peptide, reporting Goldstein's NIH-linked preclinical program. - [Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis](https://pubmed.ncbi.nlm.nih.gov/34318587/) - Yu et al., 2021 Only isolated-peptide human scalp series: a 0.5 mg/ml lab-made gel versus ketoconazole for seborrheic dermatitis (flaking, inflamed scalp), not hair counts. Authors are affiliated with the gel's producer. Patrick's peptide Q&A covering TB-500 is members-only. Attia peptide episodes treat gray-market peptides as a class without a Tβ4-for-hair analysis. No relevant public content was found from Chris Kresser or Lifespan.io. ## Grokipedia - [Thymosin beta-4](https://grokipedia.com/page/Thymosin_beta-4) Primary Grokipedia page for the endogenous 43-amino-acid peptide that the cosmetic-ingredient name sh-Oligopeptide-4 denotes, covering actin binding, repair trials, and tumor vessel-growth (angiogenesis) controversy. ## Examine No Examine.com article for sh-Oligopeptide-4, thymosin beta-4, or TB-500 was found. ## ConsumerLab No ConsumerLab article for sh-Oligopeptide-4 or full-length thymosin beta-4 was found. Hits for thymosin concerned TB-500 as a gray-market fragment, not this INCI (International Nomenclature of Cosmetic Ingredients) peptide. ## Systematic Reviews No systematic reviews or meta-analyses for sh-Oligopeptide-4 were found on PubMed as of 25 August 2026. Neither the claimed hair-growth effect nor the principal tumor-angiogenesis risk is represented by a systematic review. ## Mechanism of Action sh-Oligopeptide-4 is the cosmetic INCI name (International Nomenclature of Cosmetic Ingredients label) for recombinant human thymosin beta-4, a 43-amino-acid peptide encoded by *TMSB4X* (an X-linked gene that makes the main cellular actin buffer). Inside cells it sequesters G-actin (the unpolymerized building-block form of actin), which lets cells reorganize and migrate. The central LKKTET motif (residues 17–23) is the motility and angiogenesis cassette; the N-terminal Ac-SDKP fragment, cut by prolyl oligopeptidase (a proline-cleaving enzyme), is anti-inflammatory and antifibrotic. In follicles, thymosin beta-4 appears in bulge keratinocytes in a cycle-dependent pattern. Applied peptide is proposed to move those stem cells and their progeny to the follicle base, raise MMP-2 (matrix metalloproteinase-2, a tissue-remodeling enzyme), and increase VEGF (vascular endothelial growth factor, a microvessel-growth signal) through Wnt/β-catenin/Lef-1 (a follicle-activating developmental pathway) and the P38/ERK/AKT kinase cascades (three intracellular signaling routes that tell cells to grow or move). Rodent skin and transgenic overexpression speed the telogen-to-anagen shift (resting-to-growth). A competing finding in living human follicles grown outside the body showed 10–20% less hair-shaft elongation and earlier catagen (regression) after thymosin beta-4. Pharmacologically, intravenous recombinant peptide peaks in 3–15 minutes, has a terminal half-life of 0.5–2.1 hours, is cleared by proteases rather than cytochrome P450 enzymes (the usual drug-metabolizing liver enzymes), and does not accumulate over 10 daily doses. Selectivity is actin-binding plus downstream transcription, not a classical receptor. Tissue distribution is nearly ubiquitous except red blood cells; topical delivery of a ~5 kDa peptide into the bulge is limited unless the barrier is disrupted. ## Historical Context & Evolution Allan Goldstein's group isolated thymosin beta-4 from calf thymosin fraction 5 and published its sequence in 1981; later work showed the peptide is ubiquitous, not a thymus-only hormone. Hair interest began when Philp, Kleinman, and colleagues at the National Institutes of Health noticed faster hair at wound edges during thymosin beta-4 repair studies, then showed that topical peptide roughly doubled growing follicles on shaved rats within seven days and mobilized bulge stem cells ([Philp et al., 2004](https://pubmed.ncbi.nlm.nih.gov/14657002/)). Transgenic overexpression and knockout mice ([Gao et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26083021/); [Gao et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27130465/)) and cashmere-goat engineering extended the animal case. Cosmetic manufacturers, including Caregen with CG-Thymosin β4, listed recombinant peptide as sh-Oligopeptide-4 in hair serums. Independently, RegeneRx developed pharmaceutical thymosin beta-4 (timbetasin; RGN-259, RGN-137, RGN-352) for eye, skin, and cardiac repair; Goldstein has been closely associated with that program ([Goldstein & Kleinman, 2015](https://pubmed.ncbi.nlm.nih.gov/26096726/)). Human hair-count trials of the isolated peptide have not appeared. Clinic cocktails such as QR678 Neo fold a thymosin beta-4–mimetic peptide into multi-factor mesotherapy (intradermal scalp injections) run by the formulation's inventors. Gray-market "TB-500" injectables, usually a 7-amino-acid fragment, are often sold as thymosin beta-4 and sit on the World Anti-Doping Agency prohibited list. Opinion has not closed: rodent hair data remain consistent, [Meier et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22402437/) human follicle culture pointed the other way—likely in-vivo topical rodent skin versus high-concentration ex-vivo human follicles—and cosmetic claims outrun isolated-peptide trials. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit reaches High: isolated sh-Oligopeptide-4 has no replicated human hair-count trials; the only isolated-peptide scalp study measured seborrheic-dermatitis (flaking, inflamed scalp) scores, and hair-density figures come from multi-peptide cocktails. ### Medium 🟩 🟩 #### Improved Scalp Flaking and Barrier in Seborrheic Dermatitis A randomized comparison in adults with scalp seborrheic dermatitis (a flaking, inflamed scalp condition) tested 0.5 mg/ml recombinant thymosin beta-4 gel against 2% ketoconazole and placebo over four weeks, with follow-up to 20 weeks off treatment ([Yu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34318587/)). The gel reduced adherent-flaking and erythema (redness) scores more than ketoconazole, lowered transepidermal water loss (water escaping through the skin), raised hydration, and shifted scalp fungi and bacteria toward a healthier mix. Hair density was not an endpoint. Authors are affiliated with the gel's producer. **Magnitude:** Direction holds for 0.5 mg/ml gel over 4 weeks versus ketoconazole and placebo on adherent-flaking and erythema-area scores; the main text reports significant drops without a headline numeric delta. ### Low 🟩 #### Hair Density When Folded into an Intradermal Growth-Factor Cocktail Open-label QR678 / QR678 Neo series, a six-component intradermal blend that includes thymosin beta-4 or a mimic, report thicker terminal hair and less pull-test shedding in pattern hair loss ([Kapoor & Shome, 2018](https://pubmed.ncbi.nlm.nih.gov/29482481/); [Kapoor et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32333510/)). Results cannot isolate this peptide. The inventors developed QR678 at The Esthetic Clinics. **Magnitude:** Hair-pull improved in 83% after eight sessions in the 2018 open-label series; Phase IV pull-test stayed positive in only 12% ([Kapoor et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34997995/)). Figures are cocktail-wide, not peptide-specific. ### Speculative 🟨 #### Isolated Follicle Stem-Cell Activation ⚠️ Conflicted Rodents grow hair after peptide ([Philp et al., 2004](https://pubmed.ncbi.nlm.nih.gov/14657002/); [Gao et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26083021/)). Human follicles grew 10–20% less shaft ([Meier et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22402437/)). Net reading: rodents grow hair; living human follicles grew less; no hair-count. ## Benefit-Modifying Factors - **X-linked gene background:** *TMSB4X* sits on the X chromosome. No pharmacogenetic dosing map exists, but sex-chromosome copy number is a plausible modifier of endogenous peptide tone and of how much added peptide changes follicle signaling. - **Baseline follicle status:** Miniaturized androgenetic (pattern-hair-loss) follicles, telogen-dominant shedding, and inflamed seborrheic scalps are different substrates. The only isolated-peptide human scalp series enrolled seborrheic dermatitis, not pattern hair loss ([Yu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34318587/)). - **Sex and pattern of loss:** Androgenetic thinning follows different maps in men and women. Cocktail hair series enroll both; isolated-peptide hair-count data by sex do not exist. The encoding gene is X-linked. - **Pre-existing scalp disease:** Active infection, scarring alopecia (permanent follicle destruction), or uncontrolled autoimmune hair loss are not the populations in the rodent hair papers or the seborrheic-dermatitis gel study. - **Age:** NIH wound-and-hair work included aged rodents that still grew hair after thymosin beta-4 ([Philp et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15037013/)). Human age-stratified hair-count data for the isolated peptide are absent. - **Baseline iron and thyroid labs:** Low ferritin or untreated hypothyroidism already drive shedding. They are not shown to alter peptide follicle signaling, but they can mask or mimic a hair-count benefit. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches High: human adverse-event data are Phase 1 volunteer series and uncontrolled cocktail injections, not replicated clinical-endpoint harms of isolated scalp use. ### Medium 🟥 🟥 #### Rare Anti-Drug Antibodies After Intravenous Dosing In a recombinant intravenous Phase 1 study, anti-drug antibodies were uncommon and later negative; events were mild to moderate and similar to placebo, with no dose-limiting toxicity ([Wang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34346165/)). Synthetic intravenous peptide matched that pattern ([Ruff et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20536472/)). These data are systemic, not topical. **Magnitude:** Anti-drug antibodies were positive in 1 of 108 single-dose samples and 2 of 56 multiple-dose samples and later turned negative; topical immunogenicity rates are not reported. ### Low 🟥 #### Local Reactions After Intradermal Cocktail Injection Intradermal QR678 Neo Phase IV series, which include a thymosin beta-4 mimic among other factors, report slight itching and uncomfortable injection pain, without a serious-event cluster ([Kapoor et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34997995/)). These reactions cannot be assigned to sh-Oligopeptide-4 alone. Leave-on serums lack a published adverse-event table. **Magnitude:** Slight itching in 1.73% after session four and 1.85% after session eight in the Phase IV cocktail series (n=2,428); peptide-specific rates are not reported. ### Speculative 🟨 #### Tumor Angiogenesis and Metastasis Facilitation The peptide is overexpressed in some metastatic tumors and can raise vessel-growth signals ([Xiao et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22856429/)). Short Phase 1 follow-up found no clinical cancers. Basis is mechanistic tumor biology, not a scalp cancer trial. #### Product Identity and Contamination Labels often mix the 43-amino-acid protein with a 7-amino-acid TB-500 fragment. Sister recombinant cosmetic peptides have been criticized for weak identity ([Martínez-Carpio, 2023](https://pubmed.ncbi.nlm.nih.gov/37452558/)). Basis is class quality, not a controlled impurity trial. ## Risk-Modifying Factors - **Active or recent malignancy:** Angiogenic and motility biology is a theoretical amplifier of residual tumor vessels. No scalp-use cancer signal is documented; the concern is mechanistic ([Xiao et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22856429/)). - **Barrier disruption:** Microneedling, ablative lasers, or open dermatitis increase peptide ingress. Systemic Phase 1 exposures are brief (half-life hours) but are not a model for inflamed, needled scalp. - **Sex:** No sex-specific adverse-event split is published for topical peptide. *TMSB4X* is X-linked; that has not been tied to a clinical risk difference. - **Pre-existing scalp disease:** Broken skin, infection, or scarring alopecias change absorption and irritation risk relative to intact cosmetic use. - **Age:** Intravenous Phase 1 enrolled adults 18–50 years ([Wang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34346165/)). Older wound-trial populations exist for pharmaceutical gels, not for hair serums. - **Baseline iron and thyroid labs:** Low ferritin or untreated hypothyroidism already drive shedding; they do not change peptide biology but can confound a hair-count signal and be mistaken for peptide harm. ## Key Interactions & Contraindications - **Minoxidil (oral or topical):** Caution. Shared vasodilation and follicle-blood-flow biology could be additive for redness or hypotension if systemic exposure rises; no dedicated interaction study. Timing separation is not established. - **Anti-angiogenic cancer drugs (bevacizumab, sunitinib, lenvatinib):** Caution in anyone on active anti-VEGF therapy. Thymosin beta-4's VEGF-linked angiogenesis is mechanistically opposed; oncology teams typically treat this as a theoretical conflict. - **Other growth-factor topicals and platelet-rich plasma:** Caution, additive. QR678 already combines thymosin beta-4 mimics with vessel-, fibroblast-, insulin-like, and keratinocyte-growth-factor mimics plus copper tripeptide ([Kapoor & Shome, 2018](https://pubmed.ncbi.nlm.nih.gov/29482481/)). Further combination can raise unmeasured local-reaction and vessel-growth exposure; no dose-finding exists. - **5-alpha-reductase inhibitors (finasteride, dutasteride):** Caution not required for drug levels; the peptide is not a cytochrome P450 substrate. These drugs block conversion of testosterone to dihydrotestosterone, a separate follicle pathway. - **Ketoconazole shampoo:** Monitor. Combined use is untested and could add scalp irritation or blunt one agent's flaking effect; the gel trial used the peptide instead of, not with, 2% ketoconazole ([Yu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34318587/)). Alternating days is a practical untested mitigation. - **Immunosuppressants (systemic corticosteroids, methotrexate):** Caution on infected or barrier-broken scalps; peptide is immunomodulatory in wound models. No named contraindication threshold exists. **Populations who should avoid sh-Oligopeptide-4:** - World Anti-Doping Agency–tested athletes using injectable thymosin beta-4 or TB-500 (prohibited peptide-hormone class); leave-on cosmetics remain an untested anti-doping question. - People with untreated solid tumors or metastases when delivery is systemic, microneedled, or mesotherapy, given vessel-growth biology; no liver- or heart-failure class cutoff applies. ## Risk Mitigation Strategies - **Confirm molecular identity:** High-performance liquid chromatography and mass-spec reports showing the 43-amino-acid protein, not a 7-residue fragment, distinguish full-length peptide from TB-500 substitution. - **Barrier-limited delivery in cancer history:** Microneedling, mesotherapy, and injectables raise angiogenic tumor-vessel facilitation when a solid tumor is active or recently treated. - **Intact-barrier start:** Leave-on serum on unbroken scalp, before needling, limits systemic uptake and injection-site injury relative to disrupted skin. - **Local-reaction stop window:** Persistent injection-site pain, redness, or swelling is the QR678 local-reaction pattern; discontinuing further sessions limits ongoing site injury. - **Short initial window:** A four-week course matched the isolated-peptide scalp gel study; the hours-long plasma half-life means stopping rapidly clears systemic exposure. ## Therapeutic Protocol - **Cosmetic leave-on (Caregen-style serums):** INCI sh-Oligopeptide-4 in a leave-on hair serum, typically after washing. No independent concentration standard; the isolated human gel used 0.5 mg/ml recombinant peptide for 4 weeks ([Yu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34318587/)). - **Intradermal cocktail (QR678 Neo):** Clinic mesotherapy of a six-peptide blend including a thymosin beta-4 mimetic, often about eight sessions. Protocol popularized by Kapoor and Shome at The Esthetic Clinics, not an isolated-peptide regimen. - **Pharmaceutical and gray-market injectables:** Intravenous recombinant peptide was studied at 0.05–25 μg/kg, half-life 0.5–2.1 hours ([Wang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34346165/)). TB-500 fragment protocols are not this molecule. - **Time of day:** Not established. Leave-on products are commonly applied after evening washing so they stay on the scalp overnight. - **Half-life and splitting:** Intravenous terminal half-life is 0.5–2.1 hours with no 10-day accumulation. Topical follicle residence is unmeasured. Daily leave-on or session-based mesotherapy is used, not split oral-style dosing. - **Genetics:** No *TMSB4X* (the X-linked thymosin gene), *APOE* (lipid-transport gene), *MTHFR* (folate-cycle gene), or *COMT* (catechol-metabolizing enzyme) dosing rule exists. - **Sex:** No sex-specific dose. Cocktail series enroll men and women with pattern loss; isolated-peptide hair doses by sex are unpublished. - **Age:** Aged rodents still responded in NIH work. Human hair protocols are not age-tiered; intravenous Phase 1 capped at 50 years. - **Baseline markers:** Phototrichogram (close-up hair-count photography) density and shaft diameter, not a blood peptide level, are the practical baselines. - **Pre-existing conditions:** Seborrheic-dermatitis gel data do not transfer to scarring alopecia or active infection. Those scalps are not the studied protocol population. ## Discontinuation & Cycling - **Duration intent:** Cosmetic use is open-ended in marketing; the isolated human gel was a 4-week course with lingering barrier benefit to 20 weeks ([Yu et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34318587/)). Not a lifelong drug. - **Withdrawal:** No withdrawal syndrome is described. Intravenous peptide is gone within hours. Follicle effects, if any, would be expected to fade over a hair cycle, not overnight. - **Taper:** Not applicable for a short-half-life topical peptide. Stopping is abrupt in the published gel study. - **Cycling:** Rodent hair gains reversed after stopping in some overexpression narratives; no evidence-based on/off calendar exists for human scalp serums. - **If used with minoxidil or finasteride:** Stopping the peptide does not require tapering those agents; they have their own continuation logic. ## Sourcing and Quality - **Molecular identity:** sh-Oligopeptide-4 should be full-length recombinant thymosin beta-4 (~43 amino acids, ~5 kDa). TB-500 sold as "thymosin" is usually Ac-LKKTETQ (residues 17–23). Sequence-level certificates distinguish the 43-residue protein from that fragment. - **Third-party testing:** High-performance liquid chromatography plus mass spectrometry against a 43-residue standard. Endotoxin panels matter for recombinant *Escherichia coli* material. Purity claims without spectra are not equivalent. - **Cosmetic versus research chemical:** Leave-on cosmetics and "research use only" injectables are different legal objects. U.S. compounding-pharmacy bulk listing (section 503A) of thymosin beta-4 or TB-500 has not been established. - **Originator cosmetic peptide:** Caregen's CG-Thymosin β4 is the widely cited cosmetic raw material behind many INCI listings. Finished serums rarely disclose milligram-per-milliliter content. - **Clinic cocktails:** QR678 Neo is a proprietary blend from The Esthetic Clinics / Kapoor and Shome, not a single-peptide drug. Ingredient lists should be read as combinations. - **Class quality warning:** Recombinant cosmetic growth-factor peptides have been accused of weak identity control ([Martínez-Carpio, 2023](https://pubmed.ncbi.nlm.nih.gov/37452558/) on sh-oligopeptide-1). That critique is class-level, not a batch assay of every sh-Oligopeptide-4 serum. ## Practical Considerations - **Time to effect:** Rodent follicle doubling was reported at 7 days ([Philp et al., 2004](https://pubmed.ncbi.nlm.nih.gov/14657002/)). Human hair-cycle logic still implies 3–6 months for a countable density change. The 4-week gel study improved flaking, not counted hairs. - **Common pitfalls:** Treating TB-500 injectables as proven hair therapy; combining unmeasured serums with microneedling; reading QR678 cocktail results as isolated-peptide evidence; ignoring the human follicle-culture inhibition signal. - **Regulatory status:** Not a U.S. Food and Drug Administration–approved hair-loss drug. Cosmetic ingredient-list use is a cosmetic claim, not a drug indication. Injectable thymosin beta-4 remains investigational. TB-500 is prohibited in sport. - **Cost and access:** Cosmetic serums are widely sold; concentrations are often undisclosed. Clinic mesotherapy and gray-market vials vary widely in price and legality by jurisdiction. - **Payer incentives:** Insurers and national systems reimburse generic minoxidil and finasteride, not unapproved peptide serums or QR678 mesotherapy, a funding bias toward those follicle drugs. - **Athletes and testing:** Injectable peptide products in this family are treated as prohibited peptide hormones. Leave-on cosmetics are not a documented therapeutic-use exemption path. ## Interaction with Foundational Habits - **Sleep:** None established as a direct pharmacologic effect. Indirect: better sleep supports telogen stability; the peptide is not a sleep agent and has no published circadian dosing study. - **Nutrition:** None shown to deplete vitamins or require a named diet. Adequate protein and iron remain background follicle constraints. No food-timing rule; it is not an oral cytochrome P450 substrate. - **Exercise:** No evidence it blunts hypertrophy (muscle growth). Direct interaction none at cosmetic doses. Competitive athletes face anti-doping risk from injectable thymosin beta-4 or TB-500, independent of training effect. - **Stress management:** Indirect only. Stress-related telogen effluvium (diffuse shedding after a shock) is a different biology than bulge-cell migration. The peptide's anti-inflammatory wound data do not include a cortisol or HRV (heart-rate variability) trial. ## Monitoring Protocol & Defining Success Baseline, before starting a serum or clinic protocol, is a standardized scalp map rather than a blood peptide level: global photographs (vertex, hairline, part), a phototrichogram (close-up hair-count photography) or equivalent density and shaft-diameter reading in a tattooed or landmark-fixed window, a hair-pull test, and a short note on shedding, itch, and flaking. Androgenetic pattern (Norwood or Ludwig stage, the usual male or female pattern maps) is recorded so later photos are comparable. Blood work is not a validated thymosin beta-4 exposure marker; ferritin, TSH (thyroid-stimulating hormone), and a complete blood count are background hair-loss labs, not drug-level monitoring. Ongoing checks sit at 4 weeks (the isolated-gel window), 12 weeks, then every 3–6 months if use continues, matching a hair-cycle timescale rather than the hours-long plasma half-life. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | | --------- | ------------------------ | --------------- | ------------- | | Hair density (phototrichogram) | Change from own baseline; non-thinning vertex is often about 150–250 hairs/cm² | Detects conversion to visible terminal hair | Same site, lighting, and hair length; conventional labs have no analog | | Shaft diameter | Increase versus that person's baseline | Tracks miniaturization, the androgenetic endpoint | Pair with terminal-to-vellus (thick versus fine short hair) ratio; not a serum test | | Hair-pull test | Negative or clearly improved versus baseline | Simple shedding check | Perform away from a just-washed scalp | | Adherent flaking / erythema | Return toward that person's pre-flare state | Captures seborrheic benefit seen with the 0.5 mg/ml gel | Yu et al. used ASFS (Adherent Scalp Flaking Score) and erythema area | | Ferritin | Often targeted ≥70–100 ng/mL in longevity-oriented hair work | Rules out a common alternative cause of shedding | Conventional lower limit is often ~15–30 ng/mL; fasting not required | | TSH | Typically 0.5–2.5 mIU/L in functional practice | Hypothyroidism mimics telogen shedding | Conventional range is wider (~0.4–4.0 mIU/L) | Qualitative markers: - Daily shed in the drain or on the pillow relative to that person's baseline - Itch, burn, or new papules (small raised bumps) after application (tolerance) - Cosmetic coverage on photographs at a fixed length and lighting - For athletes, any anti-doping query about peptide products Success, if defined at all, is a documented density or diameter change at 3–6 months plus tolerable local effects—not a circulating thymosin beta-4 number. ## Emerging Research - **No registered hair trial:** ClinicalTrials.gov searches for thymosin beta-4, timbetasin, TB-500, and sh-Oligopeptide-4 with alopecia or hair loss returned no dedicated hair-regrowth study as of 25 August 2026. That absence is itself the main near-term limiter. - **Ophthalmic timbetasin, same molecule:** [SEER-2 (NCT05555589)](https://clinicaltrials.gov/study/NCT05555589) is a recruiting Phase 3 trial of 0.1% RGN-259 eye drops for neurotrophic keratopathy (a cornea that cannot heal after nerve loss), n=70. Endpoint is cornea, not hair. - **Cardiac recombinant peptide:** [NCT07586865](https://clinicaltrials.gov/study/NCT07586865) is not-yet-recruiting Phase 2 recombinant human thymosin beta-4 (NL005) for heart attack (n=189 planned). Systemic exposure data could inform vessel-growth and antibody questions. - **Human versus rodent follicle conflict:** Follow-up of [Meier et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22402437/) (human organ culture — follicles kept alive outside the body — showed less shaft growth) against [Gao et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26083021/) mouse overexpression would be the study that most changes the hair case, in either direction. - **Cocktail versus isolate:** Inventor-run QR678 Neo series continue ([Kapoor et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34997995/)). A randomized arm that drops the thymosin beta-4 mimetic would test whether this peptide is necessary or incidental. ## Conclusion sh-Oligopeptide-4 is a laboratory-made copy of thymosin beta-4, a small cell-moving protein that cosmetic hair products list as a follicle ingredient. Animal skin studies, and animals engineered to make extra amounts of the protein, show faster growth and more shafts. That is a real laboratory signal. It is not the same as a counted-hair result in people using this cosmetic peptide by itself. The only human scalp study of this peptide used alone improved flaking and barrier in a flaking scalp condition, not hair density, and was run by the gel's producer. Clinic blends that include a thymosin-beta-4–like peptide among other growth-signal copies report thicker-looking hair in uncontrolled reports from the blend's inventors at The Esthetic Clinics. A living-human-follicle experiment found slightly less shaft growth, which sits against the rodent story. Short intravenous safety studies in volunteers found mostly mild events similar to placebo. The longer-range concern is the same vessel-growing, cell-moving biology that makes the hair hypothesis interesting, because that biology also appears in some tumors. Reviews from Goldstein sit beside RegeneRx's development program for the same peptide. Marketed "TB-500" injectable products are usually a short fragment, not this 43-amino-acid protein, and sit in a poorly regulated supply chain. For a longevity-oriented adult already willing to use inconvenient follicle protocols, the evidence is a plausible mechanism, mixed animal versus human-follicle hair results, and no hair-count trial of this peptide used alone. Quality of identity on the label is part of the evidence problem, not a side issue. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**